Oncolytic Vaccinia Virus in Lung Cancer Vaccines

  • Vaccines (Basel). 2022 Feb 4;10(2):240. doi: 10.3390/vaccines10020240.
Cao-Sang Truong  1 ,  So Young Yoo  1
Affiliations
  • 1. BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Korea.
PMID: 35214699 DOI: 10.3390/vaccines10020240
Abstract

Therapeutic Cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising Cancer treatment option for effective Cancer Immunotherapy and thus can also be utilized in Cancer vaccines. Non-small cell lung Cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or Cancer vaccines, since it has a high tumor mutational burden. In this review, we will summarize recent applications of VV in lung Cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines.

Keywords
cancer vaccine; immunotherapy; non-small cell lung cancer; oncolytic virus; personalized vaccination; vaccinia virus.
Products